ArticleFrontiers in medicine2026
Severe scleroderma colopathy at initial diagnosis of systemic sclerosis in a young man: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleroderma, or systemic sclerosis (SSc) usually affects the gastrointestinal (GI) tract (up to ~90%), but severe lower GI dysmotility and intestinal pseudo- obstruction are uncommon, occurring in approximately 5. 4% of patients with SSc. We report a 25-year-old Palestinian male with a three- year history of profound unintentional weight loss (67 kg) and an eight- month history of postprandial diffuse abdominal pain, bloating, vomiting, diarrhea, and loss of appetite. Examination revealed cachexia, digital ulcers, and generalized skin thickening with hyperpigmentation. Inflammatory markers were elevated (CRP/ESR) with positive antinuclear antibody. Upper endoscopy demonstrated severe reflux esophagitis extending to the upper esophagus and mild erosive gastritis of the antrum. Colonoscopy revealed marked colonic hypomotility with minimal peristalsis and retained fecal matter. The patient was treated with mycophenolate mofetil beside symptomatic and supportive therapy (rifaximin, hyoscine butylbromide, and metoclopramide), with clinical improvement on follow-up. This case highlights severe SSc- related lower- GI dysmotility in a young male with extreme weight loss and chronic GI symptoms. Clinicians should consider SSc in patients with unexplained dysmotility/pseudo-obstruction features, especially when associated with Raynaud- spectrum vascular features, skin thickening, or positive ANA to reduce diagnostic delay and prevent further consequences, such as malnutrition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.